

PARTNERING WITH **SERVIER**

SERVIER 
moved by you



SERVIER Your strategic partner

moved by you

We are a private, independent pharmaceutical company, governed by a foundation.

Our independence enables a long-term vision and gives us the freedom to make our own strategic decisions.

We are committed to therapeutic progress to service patient needs and driven by a bold ambition to double our revenue by 2030 by reaching €10 billion in sales.

We are present in all the key innovation ecosystems in the world with capabilities ranging from R&D, commercial and manufacturing.

This includes 6 R&D centers, 19 clinical development centers, 13 manufacturing sites and commercial capabilities across the globe.

We are convinced that combining internal and external innovation will enable us to respond to major therapeutic challenges.



AMBITIOUS STRATEGY, STRONG FINANCIAL RESOURCES

Governed by Foundation: long term & independent



TRACK RECORD OF SUCCESS

In building our oncology pipeline but now also focused on partnering in rare neurological disorders



A RELIABLE, LONG- TERM PARTNER

Interested in assets from late research through to late clinical



PATIENTS AT THE HEART OF EVERYTHING WE DO

Innovating for the benefit of patients

DISCOVER SERVIER'S AREAS OF FOCUS FOR PARTNERING



Oncology



Therapeutic modalities & technologies



AI & digital technologies applied to R&D



Neurology



Drug discoveries & development technologies



Digital, Data, AI & Beyond-the-Pill

SERVIER VENTURES

Our mission

Invest in biotech and technological companies shaping the future of oncology and neurology, expanding Servier's reach across the global innovation ecosystem to advance science and unlock tomorrow's breakthrough therapies for the benefit of patients.



Contact: Alexis Vandier
Global Head of Servier Ventures
alexis.vandier@servier.com

Strategic Focus

Therapeutic focus:



Oncology
precision therapies, antibodies (mabs, ADCs, multi-specifics), small molecules



Neurology
neurodegeneration, rare neurological disorders, ASO

Investment scope:

Development stage:
Pre-IND

Geography:
primarily Europe

Asset types:
High-unmet need, strong differentiation, first-in-class, best in class, technology platforms

Our value proposition



Fund size
€200M, evergreen



Commitment:
long-term capital, no fixed cycles



Investment strategy:
minority equity investments of €5 to 10M, primarily in **Series A** financing rounds



A committed partner:
selective access to Servier expertise & capabilities



Network:
connection to Servier venture syndicates, incubators and ecosystem players












Expanding our **ONCOLOGY** pipeline to meet patient needs

We are expanding Servier's pipeline in selected oncology disease areas at all development stages, from research to late clinical.

PARTNERING INTERESTS

Key focus disease areas

PRIMARY				
	LEUKEMIA AML, ALL, MDS, MPNs	BRAIN	GI PDAC, CRC, BTC, Gastric, Esophageal, Others ¹	
SECONDARY				
	LUNG CANCER Non small cell Lung	RARE CANCERS	LYMPHOMA NHL, HL	OTHER GIST/ Sarcoma
MODALITIES				
	ANTIBODIES (mAb, ADC, bi-tri specific, TCE)	SMALL MOLECULES		

1. Others include but not limited to small intestine, anal, appendiceal, Gyn, GU, H&N, thyroid, thymoma.

Deal types

Global rights as a priority or regional (EU or US followed by China or Japan)

Late-stage clinical focus

Hematologic tumors (ALL, AML, MDS)

Solid tumors (GI & CNS as a priority)

Discovery & early-stage clinical focus

Cancer cell targeting:

Synthetic lethality

Apoptosis

Precision oncology

- Biomarker-defined populations

Immuno-oncology:

Tumor immune micro-environment

- T-cell targeting

PARTNERING CONTACTS

Global BD



Anne Dagallier, PhD

Global Head of Licensing Oncology

anne.dagallier@servier.com



Valérie Agrapart, PharmD

Director, Business Development Oncology

valerie.agrapart@servier.com

R&D Search& Evaluation



Irene Blat, PhD

Senior Director, Search & Evaluation, Oncology

irene.blat@servier.com



Alix Scholer-Dahirel, PhD

Director, Business Development Oncology

alix.scholer-dahirel@servier.com



Julie Legrand, PhD

Director, Business Development Oncology

julie.legrand@servier.com



Global BD Coordination

Trinh Lam

Project Coordination Manager, Oncology

trinh.lam@servier.com



Local BD Asia-Pacific

Cynthia Wang, MBA, MSc

Director, Business Development

cynthia.wang@servier.com












Building an innovative pipeline in **NEUROLOGY**

Our ambition is to build a new franchise in Rare Neurological Disorders by 2030. Similar to oncology, we will concentrate on hard-to-treat diseases with high medical needs.

PARTNERING INTERESTS

Key focus disease areas

PRIMARY	 RARE MOVEMENT DISORDERS¹ FA, SCA, MSA, PSP, HD	 NEUROMUSCULAR DISORDERS² ALS, SMA, DMD, FSHD, DM, MG	 REFRACTORY EPILEPSIES³ DS, LGS, JS, WS, OTHER DEES
SECONDARY	 LEUKODYSTROPHIES	 GENETICALLY DRIVEN ASD⁴ PMD, RETT, AG	 PERIPHERAL NEUROPATHIES⁵ CMT, CIDP
MODALITIES	 ANTIBODIES	 OLIGONUCLEOTIDES	 SMALL MOLECULES

1. FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease
2. ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Dystrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis
3. DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies
4. ASD: Autism Spectrum Disorders; PMD: Phelan McDermid Syndrome; AG: Angelman Syndrome
5. CMT: Charcot-Marie-Tooth; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

PARTNERING CONTACTS

Global BD



Marine Beurdeley
Global Lead
Neurology
marine.beurdeley@servier.com

R&D Search & Evaluation



Camille Nicoleau, PhD
Director, Search &
Evaluation, Neurology
camille.nicoleau@servier.com



David Theron
Project Director
Neurology
david.theron@servier.com

Local BD



Asia-Pacific

Cynthia Wang, MBA, MSc
Director, Business
Development
cynthia.wang@servier.com

Global BD Coordination



Lara-Maria Matar
Project Coordination
Manager, Neurology
laramaria.matar@servier.com



Therapeutic modalities & technologies

PARTNERING INTERESTS

Small Molecules

- Kinase, PPI, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- Targeted delivery: prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

Antibodies

- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/ Conditionally active antibody format

Oligonucleotides

- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates and drug delivery systems, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

PARTNERING CONTACTS

R&D Search & Evaluation



Georges Da Violante
**Director, Search & Evaluation,
 Enabling Technologies**
georges.da-violante@servier.com

Global BD Coordination



Delphine Duong
**Project Coordination Manager,
 Research Transactions**
delphine.duong@servier.com

Drug discovery & development technologies

PARTNERING INTERESTS

Phenotypic cell platforms & 3D models

- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a chip (liver, brain, kidney)

Protein sciences imaging

- High throughput functional & stability antibody screening
- Antigen specific immuno-oncology assays
- Microfluidic or micro array technology B-cell workflow
- Multi-protein production
- High throughput mass spectrometry based proteomic analysis approach
- Mass spectrometry target

Imaging

- High content imaging (tissues/cells) and analysis
- Multimodal platforms -multiplexing, spatial multiomics strategy, spatial phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

Sample optimization

- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughput Mass Spectrometry based proteomic analysis approach

Liquid Biopsies

- Circulating tumor DNA (ctDNA) and methylation assay development
- Circulating tumor cells (CTC)
- Exosomes or extracellular vesicle extraction from blood for biomarker identification
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

Flow chemistry

- Multistep synthesis
- Photochemistry, electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallization/drying/milling
- In line analysis
- Continuous manufacturing in pharma





AI & digital technologies applied to R&D

PARTNERING INTERESTS

Focusing on a patient centered use of AI and digital technologies to:

- Enrich our pipeline by either developing first in class new drugs or by repurposing existing drugs
- Improve treatment effectiveness, reduce adverse effects and enhance patient outcomes
- Accelerate our drug discovery & development processes

Main thematic of our data analytics strategy:

Early research

- Target identification and validation, hit screening and validation, drug design, patient stratification

Late research

- Treatment understanding, DMTA cycle optimization, disease understanding, biomarker identification

PARTNERING CONTACTS

R&D Search & Evaluation



Franck Augé, PhD

Director, Search & Evaluation,
AI & Digital Technologies

franck.auge@servier.com

Global BD Coordination



Delphine Duong

Project Coordination Manager,
Research Transactions

delphine.duong@servier.com

Therapeutic modalities:

- Small molecules, antisense oligonucleotides (ASO), antibodies (mAbs, bispecifics, ADCs)

Early development

- Disease modelling, optimization of clinical trial design, biomarker validation
- Drug product development & characterization

Late development

- Strategy for patient finding and site selection, optimization of medical authoring, patient-centric clinical trial execution, pharmacovigilance processes optimization

Digital, Data, AI opportunities & Beyond-the-Pill solutions

PARTNERING INTERESTS

Preferred digital & AI use cases

Initiatives focusing pharma operational efficiency & decision-making

- AI medical, health equity and patient insights management
- Sales forecasts, supply chain, manufacturing & employee optimization

Examples of solutions supporting health care professional (HCPs) activities

- Clinical decision support tools and clinical trials platform optimization
- Remote patient monitoring & dashboards

Examples of beyond-the-pill solutions supporting patients & caregivers

- Solutions supporting adherence (esp. chronic disease) & quality of life
- Patients journey insights and personalization (esp. oncology)
- Solutions offering education and gamification possibilities

PARTNERING CONTACTS

Digital Factory Partnering Team



Grégoire Guillet

Chief Business & Value Officer

gregoire.guillet@servier.com



Véronique Frechin

Chief Innovation Officer

veronique.frechin@servier.com



Claire Maze-Sencier

E-Health Business Analyst

claire.mazesencier@servier.com



Marianne Schuler

Scouting Officer

marianne.schuler@servier.com

Preferred modalities

Geographic scope

- Worldwide (or regional)

Deal types

- Co-development, licenses, strategic partnerships & beyond

Preferred maturity stage & technical aspects

- Ready to use solutions
- Previous pharma partnerships
- Medical device (depending on use case)
- Clinical benefits targeted





Partner with us.